
Bridget E. Bunner
Examiner (ID: 17180)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647, 1644 |
| Total Applications | 1462 |
| Issued Applications | 724 |
| Pending Applications | 157 |
| Abandoned Applications | 602 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16075627
[patent_doc_number] => 20200191800
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => METHODS FOR TREATING DRUG RESISTANT CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/622796
[patent_app_country] => US
[patent_app_date] => 2018-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622796
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/622796 | METHODS FOR TREATING DRUG RESISTANT CANCERS | Jun 13, 2018 | Abandoned |
Array
(
[id] => 14977927
[patent_doc_number] => 10442864
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-15
[patent_title] => Anti-Tie2 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/007399
[patent_app_country] => US
[patent_app_date] => 2018-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 14300
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007399
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/007399 | Anti-Tie2 antibodies and uses thereof | Jun 12, 2018 | Issued |
Array
(
[id] => 13593335
[patent_doc_number] => 20180348216
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => CD318 AS A MARKER FOR, AND CD318 INHIBITION AS A TREATMENT FOR, AUTOIMMUNE DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/997248
[patent_app_country] => US
[patent_app_date] => 2018-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10369
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997248
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/997248 | CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease | Jun 3, 2018 | Issued |
Array
(
[id] => 13590081
[patent_doc_number] => 20180346589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => MECHANO-ACTIVATED CONTROL OF GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 15/994330
[patent_app_country] => US
[patent_app_date] => 2018-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15994330
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/994330 | Synthetic notch protein for modulating gene expression | May 30, 2018 | Issued |
Array
(
[id] => 13840635
[patent_doc_number] => 20190023802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-24
[patent_title] => ANTI-JAGGED1 ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 15/993448
[patent_app_country] => US
[patent_app_date] => 2018-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993448
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/993448 | Anti-Jagged1 antigen binding proteins | May 29, 2018 | Issued |
Array
(
[id] => 15931207
[patent_doc_number] => 20200157237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => LYMPHOCYTE ANTIGEN CD5LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/616536
[patent_app_country] => US
[patent_app_date] => 2018-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 92492
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616536
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/616536 | LYMPHOCYTE ANTIGEN CD5LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHODS OF USE THEREOF | May 24, 2018 | Abandoned |
Array
(
[id] => 13400043
[patent_doc_number] => 20180251564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-06
[patent_title] => Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation
[patent_app_type] => utility
[patent_app_number] => 15/980411
[patent_app_country] => US
[patent_app_date] => 2018-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980411
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/980411 | Anti-BAFFR antibody therapeutic formulations | May 14, 2018 | Issued |
Array
(
[id] => 15866313
[patent_doc_number] => 20200140560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => PROTEASE BASED SWITCH CHIMERIC ANTIGEN RECEPTORS FOR SAFER CELL IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 16/612280
[patent_app_country] => US
[patent_app_date] => 2018-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17780
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/612280 | PROTEASE BASED SWITCH CHIMERIC ANTIGEN RECEPTORS FOR SAFER CELL IMMUNOTHERAPY | May 10, 2018 | Abandoned |
Array
(
[id] => 13590015
[patent_doc_number] => 20180346556
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WTIH A DLL4 ANTAGONIST AND AN ANTI-HYPERTENSIVE AGENT
[patent_app_type] => utility
[patent_app_number] => 15/966247
[patent_app_country] => US
[patent_app_date] => 2018-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966247
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/966247 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | Apr 29, 2018 | Issued |
Array
(
[id] => 14199017
[patent_doc_number] => 10266602
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-23
[patent_title] => Compositions and methods for diagnosis and treatment of hepatic cancers
[patent_app_type] => utility
[patent_app_number] => 15/964248
[patent_app_country] => US
[patent_app_date] => 2018-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 71
[patent_no_of_words] => 33171
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964248
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/964248 | Compositions and methods for diagnosis and treatment of hepatic cancers | Apr 26, 2018 | Issued |
Array
(
[id] => 15866201
[patent_doc_number] => 20200140504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => PEPTIDE FOR TOLL-LIKE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 16/610278
[patent_app_country] => US
[patent_app_date] => 2018-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11624
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610278
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/610278 | Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same | Apr 24, 2018 | Issued |
Array
(
[id] => 16634333
[patent_doc_number] => 10912820
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-09
[patent_title] => Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias
[patent_app_type] => utility
[patent_app_number] => 15/956343
[patent_app_country] => US
[patent_app_date] => 2018-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 8505
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956343
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/956343 | Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias | Apr 17, 2018 | Issued |
Array
(
[id] => 13490201
[patent_doc_number] => 20180296643
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-18
[patent_title] => SDF-1 FOR ANAL AND SPHINCTER WOUND HEALING
[patent_app_type] => utility
[patent_app_number] => 15/955221
[patent_app_country] => US
[patent_app_date] => 2018-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955221
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/955221 | SDF-1 FOR ANAL AND SPHINCTER WOUND HEALING | Apr 16, 2018 | Abandoned |
Array
(
[id] => 15527215
[patent_doc_number] => 20200055913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION
[patent_app_type] => utility
[patent_app_number] => 16/498365
[patent_app_country] => US
[patent_app_date] => 2018-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498365
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498365 | HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION | Apr 11, 2018 | Abandoned |
Array
(
[id] => 15527215
[patent_doc_number] => 20200055913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION
[patent_app_type] => utility
[patent_app_number] => 16/498365
[patent_app_country] => US
[patent_app_date] => 2018-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498365
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498365 | HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION | Apr 11, 2018 | Abandoned |
Array
(
[id] => 16665131
[patent_doc_number] => 10934364
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-02
[patent_title] => Method for in vivo expansion of T regulatory cells
[patent_app_type] => utility
[patent_app_number] => 15/950962
[patent_app_country] => US
[patent_app_date] => 2018-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 1
[patent_no_of_words] => 19517
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950962
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/950962 | Method for in vivo expansion of T regulatory cells | Apr 10, 2018 | Issued |
Array
(
[id] => 15931761
[patent_doc_number] => 20200157514
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => Polypeptide Set to Be Used in Light Dependent Gene Recombination
[patent_app_type] => utility
[patent_app_number] => 16/604351
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604351
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604351 | Polypeptide set to be used in light dependent gene recombination | Apr 9, 2018 | Issued |
Array
(
[id] => 13357335
[patent_doc_number] => 20180230207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-16
[patent_title] => NOTCH INHIBITION IN THE TREATMENT AND PREVENTION OF NONALCOHOLIC FATTY LIVER DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/949025
[patent_app_country] => US
[patent_app_date] => 2018-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14039
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949025
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/949025 | Notch inhibition in the treatment and prevention of nonalcoholic fatty liver disease | Apr 8, 2018 | Issued |
Array
(
[id] => 16476242
[patent_doc_number] => 10851171
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-01
[patent_title] => Method for the selection of antibodies against BCMA
[patent_app_type] => utility
[patent_app_number] => 15/945554
[patent_app_country] => US
[patent_app_date] => 2018-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 8
[patent_no_of_words] => 34689
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15945554
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/945554 | Method for the selection of antibodies against BCMA | Apr 3, 2018 | Issued |
Array
(
[id] => 13325907
[patent_doc_number] => 20180214491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-02
[patent_title] => COMPOSITIONS AND METHODS FOR EXPANSION OF EMBRYONIC HEMATOPOIETIC STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 15/939199
[patent_app_country] => US
[patent_app_date] => 2018-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25521
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -99
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15939199
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/939199 | Compositions and methods for expansion of embryonic hematopoietic stem cells | Mar 27, 2018 | Issued |